Dovitinib-RIBOTAC TFA

Overview

Dovitinib RIBOTAC TFA is an RNA-targeting RIBOTAC degrader that can specifically bind to and degrade pre-miR-21 . Dovitinib RIBOTAC TFA can inhibit the metastasis of breast cancer and has anti-tumor activity.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Programmed Cell Death 4 (PDCD4) | Products > Signaling Pathways > RIBOTAC | Products > Signaling Pathways > PPAR | Products > Signaling Pathways > DNA/RNA Synthesis

Product Information

• Catalog No.: HY-139682A
• CAS No.: 2759351-69-2
• Molecular Formula: C53H57F4N9O12S
• Molecular Weight: 1120.13
• Purity: 98.35%
• Storage: 4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
• Availability: In-stock

Source

Original product source